186 related articles for article (PubMed ID: 32847115)
1. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.
Liu F; Kalpage HA; Wang D; Edwards H; Hüttemann M; Ma J; Su Y; Carter J; Li X; Polin L; Kushner J; Dzinic SH; White K; Wang G; Taub JW; Ge Y
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847115
[TBL] [Abstract][Full Text] [Related]
2. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
4. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
6. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
7. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.
Hurrish KH; Su Y; Patel S; Ramage CL; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
Res Sq; 2023 Apr; ():. PubMed ID: 37162954
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells.
Cho H; Jang JE; Eom JI; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
Exp Hematol Oncol; 2021 Apr; 10(1):28. PubMed ID: 33858507
[TBL] [Abstract][Full Text] [Related]
9. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
Li X; Su Y; Hege K; Madlambayan G; Edwards H; Knight T; Polin L; Kushner J; Dzinic SH; White K; Yang J; Miller R; Wang G; Zhao L; Wang Y; Lin H; Taub JW; Ge Y
Haematologica; 2021 May; 106(5):1262-1277. PubMed ID: 32165486
[TBL] [Abstract][Full Text] [Related]
10. DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation.
Jang JE; Hwang DY; Eom JI; Cheong JW; Jeung HK; Cho H; Chung H; Kim JS; Min YH
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765703
[TBL] [Abstract][Full Text] [Related]
11. c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia.
Liu S; Qiao X; Wu S; Gai Y; Su Y; Edwards H; Wang Y; Lin H; Taub JW; Wang G; Ge Y
Apoptosis; 2022 Dec; 27(11-12):913-928. PubMed ID: 35943677
[TBL] [Abstract][Full Text] [Related]
12. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Sharma P; Pollyea DA
Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
[TBL] [Abstract][Full Text] [Related]
13. An inhibitor of oxidative phosphorylation exploits cancer vulnerability.
Molina JR; Sun Y; Protopopova M; Gera S; Bandi M; Bristow C; McAfoos T; Morlacchi P; Ackroyd J; Agip AA; Al-Atrash G; Asara J; Bardenhagen J; Carrillo CC; Carroll C; Chang E; Ciurea S; Cross JB; Czako B; Deem A; Daver N; de Groot JF; Dong JW; Feng N; Gao G; Gay J; Do MG; Greer J; Giuliani V; Han J; Han L; Henry VK; Hirst J; Huang S; Jiang Y; Kang Z; Khor T; Konoplev S; Lin YH; Liu G; Lodi A; Lofton T; Ma H; Mahendra M; Matre P; Mullinax R; Peoples M; Petrocchi A; Rodriguez-Canale J; Serreli R; Shi T; Smith M; Tabe Y; Theroff J; Tiziani S; Xu Q; Zhang Q; Muller F; DePinho RA; Toniatti C; Draetta GF; Heffernan TP; Konopleva M; Jones P; Di Francesco ME; Marszalek JR
Nat Med; 2018 Jul; 24(7):1036-1046. PubMed ID: 29892070
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism.
Li G; Li D; Yuan F; Cheng C; Chen L; Wei X
Ann Transl Med; 2021 Oct; 9(20):1575. PubMed ID: 34790781
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance.
Garciaz S; Saillard C; Hicheri Y; Hospital MA; Vey N
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830763
[TBL] [Abstract][Full Text] [Related]
16. Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia.
Knight T; Edwards H; Taub JW; Ge Y
Cancer Manag Res; 2019; 11():3197-3213. PubMed ID: 31118772
[TBL] [Abstract][Full Text] [Related]
17. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.
Sharon D; Cathelin S; Mirali S; Di Trani JM; Yanofsky DJ; Keon KA; Rubinstein JL; Schimmer AD; Ketela T; Chan SM
Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666400
[TBL] [Abstract][Full Text] [Related]
19. Combined venetoclax and alvocidib in acute myeloid leukemia.
Bogenberger J; Whatcott C; Hansen N; Delman D; Shi CX; Kim W; Haws H; Soh K; Lee YS; Peterson P; Siddiqui-Jain A; Weitman S; Stewart K; Bearss D; Mesa R; Warner S; Tibes R
Oncotarget; 2017 Dec; 8(63):107206-107222. PubMed ID: 29291023
[TBL] [Abstract][Full Text] [Related]
20. Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia.
Zhou C; Wang Z; Yang S; Li H; Zhao L
Front Oncol; 2022; 12():864430. PubMed ID: 35847946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
